Hormonoresistance in advanced breast cancer: a new revolution in endocrine therapy.
about
Efficacy of palbociclib plus fulvestrant after everolimus in hormone receptor-positive metastatic breast cancer.PI3K/mTOR Inhibitors in the Treatment of Luminal Breast Cancer. Why, When and to Whom?Hydroquinone Exhibits In Vitro and In Vivo Anti-Cancer Activity in Cancer Cells and Mice.Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer.Study on Biological Characteristics and Mechanism of Paclitaxel Induced Drug Resistance in Endometrial Carcinoma Cells
P2860
Hormonoresistance in advanced breast cancer: a new revolution in endocrine therapy.
description
2017 nî lūn-bûn
@nan
2017 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի մարտին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
Hormonoresistance in advanced breast cancer: a new revolution in endocrine therapy.
@ast
Hormonoresistance in advanced breast cancer: a new revolution in endocrine therapy.
@en
type
label
Hormonoresistance in advanced breast cancer: a new revolution in endocrine therapy.
@ast
Hormonoresistance in advanced breast cancer: a new revolution in endocrine therapy.
@en
prefLabel
Hormonoresistance in advanced breast cancer: a new revolution in endocrine therapy.
@ast
Hormonoresistance in advanced breast cancer: a new revolution in endocrine therapy.
@en
P2093
P2860
P356
P1476
Hormonoresistance in advanced breast cancer: a new revolution in endocrine therapy
@en
P2093
Anne Patsouris
Carole Gourmelon
Dominique Berton Rigaud
Emmanuelle Bourbouloux
Mario Campone
Patrick Soulié
Paule Augereau
Sophie Abadie Lacourtoisie
P2860
P304
P356
10.1177/1758834017693195
P577
2017-03-14T00:00:00Z